Zobrazeno 1 - 5
of 5
pro vyhledávání: '"van Oorschot DAM"'
Autor:
Belizan M; Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina., Augustovski F; Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina; Center for Research in Epidemiology and Public Health (CIESP), Buenos Aires, Argentina., Bardach A; Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina; Center for Research in Epidemiology and Public Health (CIESP), Buenos Aires, Argentina., Pinto T; Value Evidence Outcome Department, GlaxoSmithKline, Wavre, Belgium. Electronic address: thatiana.x.pinto@gsk.com., Villarejo A; Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina., Lazo E; Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina., Cordo MV; Instituto Médico Platense (IMP), La Plata, Argentina., van Oorschot DAM; Value Evidence Outcome Department, GlaxoSmithKline, Wavre, Belgium.
Publikováno v:
Value in health regional issues [Value Health Reg Issues] 2024 Sep 03; Vol. 44, pp. 101044. Date of Electronic Publication: 2024 Sep 03.
Autor:
Gómez JA; Value Evidence & Outcomes, Vaccines, Emerging Markets, GSK, Buenos Aires 1429, Argentina., Cintra O; Medical Affairs, Vaccines, Emerging Markets, GSK, Sao Paulo 04001-083, Brazil., Berzanskis A; Medical Affairs, Vaccines, Emerging Markets, GSK, London WC1A 1DG, UK., Pacheco S; Medical Affairs, Vaccines, Emerging Markets, GSK, Mexico City 03330, Mexico., Jaswantlal H; Medical Affairs, Vaccines, Emerging Markets, GSK, Petaling Jaya 47800, Selangor, Malaysia., Hasnaoui AE; Medical Affairs, Vaccines, Emerging Markets, GSK, Dubai 50199, United Arab Emirates., van Oorschot DAM; Medical Evidence Generation Emerging Markets, Vaccines GSK, 1300 Wavre, Belgium., Guzman-Holst A; Medical Evidence Generation Emerging Markets, Vaccines GSK, 1300 Wavre, Belgium.
Publikováno v:
Infectious disease reports [Infect Dis Rep] 2024 Aug 15; Vol. 16 (4), pp. 750-762. Date of Electronic Publication: 2024 Aug 15.
Autor:
Han R; GSK, Wavre, Belgium. ru.x.han@gsk.com., San Martin P; GSK, Wavre, Belgium., Ahmed N; GSK, London, UK., Guzman-Holst A; GSK, Wavre, Belgium., Mohy A; GSK, Wavre, Belgium., Pinto T; GSK, Wavre, Belgium., de Veras B; GSK, Rio de Janeiro, Brazil., Gomez JA; GSK, Buenos Aires, Argentina., Bibera GL; GSK, Manila, Philippines., van Oorschot DAM; GSK, Wavre, Belgium.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2024 Apr; Vol. 13 (4), pp. 761-778. Date of Electronic Publication: 2024 Mar 17.
Autor:
Han R; Value Evidence Outcome Department, GSK, Wavre, Belgium., Gomez JA; Value Evidence Outcome Department, GSK, Buenos Aires, Argentina., de Veras B; Value Evidence Outcome Department, GSK, Rio de Janeiro, Brazil., Pinto T; Value Evidence Outcome Department, GSK, Wavre, Belgium., Guzman-Holst A; Value Evidence Outcome Department, GSK, Wavre, Belgium., Nieto J; Medical Affairs Department, GSK, Panama City, Panama., van Oorschot DAM; Value Evidence Outcome Department, GSK, Wavre, Belgium.
Publikováno v:
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2164144. Date of Electronic Publication: 2023 Feb 23.
Autor:
van Oorschot DAM; GSK, Wavre, Belgium., Hunjan M; GSK, Uxbridge, UK., Bracke B; GSK, Wavre, Belgium., Lorenc S; Freelance on behalf of GSK, Wavre, Belgium., Curran D; GSK, Wavre, Belgium., Starkie-Camejo H; GSK, Uxbridge, UK.
Publikováno v:
BMJ open [BMJ Open] 2019 May 05; Vol. 9 (5), pp. e025553. Date of Electronic Publication: 2019 May 05.